CN113663120B - Hemostatic sponge cushion core and preparation method thereof - Google Patents
Hemostatic sponge cushion core and preparation method thereof Download PDFInfo
- Publication number
- CN113663120B CN113663120B CN202111144981.3A CN202111144981A CN113663120B CN 113663120 B CN113663120 B CN 113663120B CN 202111144981 A CN202111144981 A CN 202111144981A CN 113663120 B CN113663120 B CN 113663120B
- Authority
- CN
- China
- Prior art keywords
- hemostatic sponge
- water
- hemostatic
- core
- gelatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002439 hemostatic effect Effects 0.000 title claims abstract description 86
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 40
- 108010010803 Gelatin Proteins 0.000 claims description 25
- 239000008273 gelatin Substances 0.000 claims description 25
- 229920000159 gelatin Polymers 0.000 claims description 25
- 235000019322 gelatine Nutrition 0.000 claims description 25
- 235000011852 gelatine desserts Nutrition 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 23
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 21
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 18
- 239000012153 distilled water Substances 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 16
- 238000004108 freeze drying Methods 0.000 claims description 11
- 238000004132 cross linking Methods 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 10
- 238000007710 freezing Methods 0.000 claims description 8
- 230000008014 freezing Effects 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 6
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 claims description 5
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 239000002390 adhesive tape Substances 0.000 claims description 2
- 230000023597 hemostasis Effects 0.000 abstract description 13
- 239000000853 adhesive Substances 0.000 abstract description 3
- 230000001070 adhesive effect Effects 0.000 abstract description 3
- 239000011505 plaster Substances 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 238000000502 dialysis Methods 0.000 abstract description 2
- 238000005187 foaming Methods 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 16
- 208000027418 Wounds and injury Diseases 0.000 description 16
- 239000000463 material Substances 0.000 description 14
- 229920001661 Chitosan Polymers 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000034158 bleeding Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 239000003114 blood coagulation factor Substances 0.000 description 4
- 229940019700 blood coagulation factors Drugs 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000002861 polymer material Substances 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 206010051373 Wound haemorrhage Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- LRWZZZWJMFNZIK-UHFFFAOYSA-N 2-chloro-3-methyloxirane Chemical compound CC1OC1Cl LRWZZZWJMFNZIK-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000002346 layers by function Substances 0.000 description 1
- 239000008258 liquid foam Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000020971 positive regulation of blood coagulation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/104—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Surgery (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a hemostatic sponge pad core and a preparation method thereof, wherein hemostatic sponge is smeared on a water absorption pad in a foaming stage and does not disappear after being dried, and further the hemostatic sponge pad core can be prepared into functional dressing with adhesive plaster, and is suitable for hemostasis and wound protection after body surface dialysis and operation of a human body.
Description
[ technical field ] A
The invention relates to the technical field of polymer medical materials, in particular to a hemostatic sponge cushion core and a preparation method thereof.
[ background ] A method for producing a semiconductor device
The hemostatic sponge is used for rapidly stopping bleeding, inhibiting bacteria and resisting infection, absorbing a large amount of blood and tissue seepage and accelerating wound healing. The normal hemostasis of the body mainly depends on the structure and function of the intact blood vessel wall, the effective quality and quantity of blood platelets and the activity of normal blood coagulation factors, wherein the effects of the blood platelets with negative charges and the blood coagulation factors are the main. The hemostatic sponge is a hemostatic material which is fine, porous and positively charged, and can immediately adhere and aggregate platelets when contacting human blood, so that the blood forms thrombus and blocks wounds, various factors related to blood coagulation are released, and the blood forms stable fibrin polymers under the combined action of endogenous and exogenous blood coagulation paths, so that blood clots are formed, and the purpose of wound hemostasis is achieved.
The hemostatic sponge is mainly used for wound surface hemostasis and operation wound healing in surgery, obstetrics and gynecology, orthopedics, stomatology and other operations; first-aid hemostasis treatment for superficial burn, scald, accidental wound, battlefield rescue, industrial and mining accident wound and the like. According to different parts, selecting hemostatic sponge with corresponding shape or cutting into required shape under aseptic condition, and applying after gently kneading. In wound emergency treatment and surgical operation, wound bleeding and bleeding are frequently encountered problems, the life is threatened by the massive loss of blood, and meanwhile, the bleeding or bleeding is a natural microbial culture medium, so that the infection probability is increased, and the success rate of the operation is reduced. Good hemostasis techniques are the key to successful surgery, so surgical hemostasis is one of the cores of surgical techniques. Temporarily controlling bleeding, covering and binding the wound as soon as possible, isolating the wound from the outside to reduce the infection chance and creating good wound surface conditions for debridement. The ideal hemostatic material should have the characteristics of rapid hemostasis, no irritation, no acute toxicity, no chronic toxicity, no teratogenicity, carcinogenicity and the like, and has controllable degradation speed meeting different requirements and excellent biocompatibility.
The hemostatic sponge is mainly classified into absorbable gelatin hemostatic sponge, chitosan hemostatic sponge, collagen hemostatic sponge, etc. according to different materials. With the research and development of biomedical polymer materials such as natural polymer materials like cellulose and chitin and synthetic polymer materials like polyvinyl alcohol and collagen, the application and development of hemostatic materials have been greatly improved:
1. gelatin: the absorbable gelatin sponge is the most common hemostatic material in clinic at present, has long use history, more definite use effect and low price, can be applied, wrapped and embolized by using a mode, and is suitable for trauma and bleeding, bleeding and deep trauma of surgery. The gelatin hemostatic product is a safe and reliable product on the whole, has no antigenicity, does not produce anaphylactic reaction, and has no inflammatory reaction to surrounding tissues when being packed with a wound. However, the gelatin hemostatic product has the disadvantages that the mechanical property is poor, the gelatin hemostatic product is easy to damage after encountering blood, and the traction capacity of platelets for blood cells is very weak, so that the gelatin hemostatic product is difficult to stop for large wound bleeding. It has poor adhesion, is easy to fall off, and is also not easy to fix on the wound surface of the internal organ. In addition, when the gelatin sponge promotes blood coagulation, the activation of blood coagulation factors in body blood is needed to be realized, so the hemostatic effect on patients with blood coagulation mechanism disorder is not ideal, and a high-performance gelatin hemostatic product is obtained by compounding the gelatin hemostatic product with other types of hemostatic materials.
2. And (3) chitosan: the cationic cellulose is the only polymer material which is known to exist in nature and has wide biodegradation distribution, exists in a large number in shells of insects and crustaceans and cell walls of fungi, is the second most renewable resource next to cellulose on the earth, is insoluble in water and organic solvents, and is difficult to be utilized by human bodies. The product obtained by deacetylation is called chitosan (chemical name is (1-4) -amino-2-deoxyamino-D-glucose), and can be absorbed and utilized by human body. The polysaccharide can be biosynthesized and biodegraded, has good biocompatibility with animal organ tissues and cells, is non-toxic, and the low-molecular oligosaccharide generated in the degradation process is not accumulated in vivo and has almost no immunogenicity. The chitosan hemostatic sponge is suitable for hemostasis and intractable nasal hemorrhage of various body surface wounds (such as bruise, vascular puncture, tube placement, oral cavity, ear-nose-throat operation wounds and the like) and body surface granulation wounds. The chitosan and the derivatives thereof have good biocompatibility and can be degraded in a human body, the degradation products are safe and non-toxic, the chitosan and the derivatives thereof have positive charges and have the antibacterial and anti-inflammatory effects, the sponge made of the chitosan can still keep the sponge after meeting water, and the gelatin sponge has no elasticity, so that the compression hemostasis effect of the gelatin sponge is poor; and chitosan has good effects of promoting wound healing, inhibiting the growth of fibroblasts and reducing the formation of scars. However, pure chitosan hemostatic materials are not stable in hemostatic effect against severe bleeding, and other blood coagulation factors and hemostatic materials need to be combined to improve the hemostatic effect.
3. Collagen, also known as collagen: is a group of scleroproteins which are most abundant and widely distributed in vertebrate bodies, is an important material for composing the body structures of the vertebrates, and is the most abundant protein in mammals. Collagen is composed of multiple glycoprotein molecules, is the main protein component of connective tissue, and accounts for 20-30% of total protein of body. Approximately half of the body's collagen is present in the skin, and it accounts for 70% of the dry weight of the dermis and tendons, corresponding to 6% of body weight. The collagen material has many excellent properties, such as biodegradability, low antigenicity, cell adaptability, biocompatibility, cell proliferation promoting effect, platelet aggregation accelerating effect, etc. The rapid and efficient hemostasis on the wound surface is completed. After the hemostasis process is finished, the collagen material can be automatically degraded in the body, additional dismantling is not needed, and the use is convenient.
Although both collagen and chitosan have good biocompatibility, the pure use of collagen or chitosan hemostatic material has poor mechanical properties and unsatisfactory hemostatic effect, and cannot meet the requirements of clinical operations,
[ summary of the invention ]
Aiming at the defects that the existing hemostatic sponge is generally prepared from collagen or chitosan hemostatic materials, so that the mechanical property is poor, the hemostatic effect is not ideal, the requirements of clinical operations cannot be met and the like, the invention provides the hemostatic sponge pad core and the preparation method thereof.
The purpose of the invention is realized by the following technical scheme:
the preparation method of the hemostatic sponge cushion core comprises the following steps:
1) Preparing raw materials according to the proportion: gelatin (9.5-10.5) g, distilled water (88-92) mL, 0.25% (v/v) glutaraldehyde solution (2.8-3.2) mL, 0.5% (v/v) formaldehyde (2.4-2.6) mL;
2) Pouring gelatin into distilled water, soaking for 10 minutes, heating in water bath, stirring for dissolving, adding 0.5% (v/v) formaldehyde, and stirring at high speed to obtain a liquid foam mixed solution;
3) Injecting the mixed solution obtained in the previous step into moulds with different specifications, paving water-absorbing pad cores at the bottom of the moulds, pre-freezing at-40 to-80 ℃, and then performing freeze drying to obtain the water-absorbing pad cores with sponges;
4) And (3) crosslinking the water-absorbing pad core with the sponge obtained in the previous step by adopting 0.25% (v/v) glutaraldehyde solution, washing the water-absorbing pad core with distilled water for a plurality of times after crosslinking, then carrying out freeze drying and forming again, sealing, and carrying out cobalt-60 sterilization to obtain the hemostatic sponge pad core.
In the invention:
the raw materials prepared according to the proportion in the step 1) are 10g of gelatin, 90g of distilled water, 3ml of 0.25% glutaraldehyde solution and 2.5ml of 0.5% formaldehyde.
Heating in water bath at 60-70 deg.C in step 2).
The high-speed stirring in the step 2) is stirring at 200-400rpm for 20-30min.
Washing for a plurality of times in the step 4), namely washing for 2-4 times.
Further, after the step 4) of freeze drying and molding again, adhesive plaster is pasted at the bottom of the hemostatic sponge cushion core.
The invention also relates to the hemostatic sponge cushion core prepared by the preparation method of the hemostatic sponge cushion core, which is suitable for hemostasis and wound protection after body surface dialysis and operation.
Compared with the prior art, the invention has the following advantages:
1. the functional layer raw materials of the existing hemostatic sponge cushion core are gelatin and high-protein products, and the hemostatic sponge is not used to prepare functional dressing capable of being provided with adhesive plaster at present.
2. The preparation method of the hemostatic sponge cushion core provides technical support for producing functional dressing, and the dried material can be cut and coiled according to different thickness requirements, so that the hemostatic sponge cushion core is convenient for mechanical production.
[ detailed description ] embodiments
The following examples are provided to further illustrate the embodiments of the present invention.
Example 1:
the preparation method of the hemostatic sponge cushion core comprises the following steps:
1) Preparing raw materials according to the proportion: 10g of gelatin, 90g of distilled water, 3ml of 0.25% glutaraldehyde solution and 2.5ml of 0.5% formaldehyde;
2) Pouring gelatin into distilled water, soaking for 10 min, heating in 65 deg.C water bath, stirring for dissolving, adding 0.5% (v/v) formaldehyde, and stirring at high speed (400rpm, 20min) to obtain foam liquid mixed solution;
3) Injecting the mixed solution obtained in the previous step into moulds with different specifications, paving water-absorbing pad cores at the bottom of the moulds, pre-freezing at-40 to-80 ℃, and then performing freeze drying to obtain the water-absorbing pad cores with sponges;
4) And (2) crosslinking the water absorption pad core with the sponge obtained in the previous step by adopting 0.25% (v/v) glutaraldehyde solution, washing the crosslinked pad core for several times by using distilled water after crosslinking is finished, then carrying out freeze drying and forming again, pasting adhesive tape on the bottom of the hemostatic sponge pad core, sealing, and then sterilizing by adopting cobalt-60 to obtain the hemostatic sponge pad core.
Example 2:
the preparation method of the hemostatic sponge cushion core comprises the following steps:
1) Preparing raw materials according to the proportion: 9.5g of gelatin, 92mL of distilled water, 2.8mL of 0.25% (v/v) glutaraldehyde solution, and 2.6mL of 0.5% (v/v) formaldehyde;
2) Pouring gelatin into distilled water, soaking for 10 min, heating in water bath at 60 deg.C, stirring for dissolving, adding 0.5% (v/v) formaldehyde, and stirring at high speed (300rpm, 25min) to obtain foam liquid mixed solution;
3) Injecting the mixed solution obtained in the previous step into moulds with different specifications, paving water-absorbing pad cores at the bottom of the moulds, pre-freezing at-40 to-80 ℃, and then performing freeze drying to obtain the water-absorbing pad cores with sponges;
4) And (3) crosslinking the water-absorbing pad core with the sponge obtained in the previous step by adopting 0.25% (v/v) glutaraldehyde solution, washing the crosslinked pad core for several times by using distilled water after crosslinking is finished, then carrying out freeze drying and forming again, sealing, and carrying out cobalt-60 sterilization to obtain the hemostatic sponge pad core.
Example 3:
the preparation method of the hemostatic sponge cushion core comprises the following steps:
1) Preparing raw materials according to the proportion: 10.5g of gelatin, 88mL of distilled water, 3.2mL of 0.25% (v/v) glutaraldehyde solution, and 2.4mL of 0.5% (v/v) formaldehyde;
2) Pouring gelatin into distilled water, soaking for 10 minutes, heating in 70 ℃ water bath, stirring for dissolving, adding 0.5% (v/v) formaldehyde, and uniformly stirring at high speed (200rpm, 30min) to obtain a foam liquid mixed solution;
3) Injecting the mixed solution obtained in the previous step into moulds with different specifications, paving water-absorbing pad cores at the bottom of the mould, pre-freezing at-40 to-80 ℃, and then performing freeze drying to obtain the water-absorbing pad cores with sponges;
4) And (3) crosslinking the water-absorbing pad core with the sponge obtained in the previous step by adopting 0.25% (v/v) glutaraldehyde solution, washing the crosslinked pad core for several times by using distilled water after crosslinking is finished, then carrying out freeze drying and forming again, sealing, and carrying out cobalt-60 sterilization to obtain the hemostatic sponge pad core.
Comparative example:
according to CN202110319395.1, a degradable hemostatic sponge, a preparation method and application thereof, and a degradable drug-loaded hemostatic sponge, the provided preparation method of the degradable hemostatic sponge comprises the following steps:
1) Weighing 100.0g of potato starch in a reaction kettle, adding 4900ml of water into the reaction kettle, setting the temperature of a jacket reaction kettle to be 80 ℃, and stirring at a constant temperature of 200rpm for 1h; reducing the temperature of a jacket reaction kettle to 50 ℃, adjusting the pH of reaction liquid to 9 by using a NaOH solution with the concentration of 1mol/L, dropwise adding 10ml of epoxy chloropropane aqueous solution into the reaction liquid by using a constant-pressure titration funnel, reacting at a high temperature for 4 hours, pouring out the reaction liquid after the reaction is finished, cooling, separating out a product by using 12.5L of absolute ethyl alcohol, washing the product by using 2L of absolute ethyl alcohol for 2-3 times, and drying at 50 ℃ for 24 hours to obtain the crosslinked modified potato starch;
2) Weighing 1.0g of carboxymethyl cellulose in 39ml of water, stirring at 400rpm in a water bath at 40 ℃ for 4 hours to completely dissolve the carboxymethyl cellulose into uniform transparent gel, adjusting the pH value of the carboxymethyl cellulose solution to 3 by using 1mol/L HCl, and cooling to room temperature for later use;
3) Weighing 2.0g of cross-linked modified potato starch in 58ml of water, stirring and dissolving at normal temperature for 20min to ensure that the cross-linked starch absorbs water and is saturated, pouring the cross-linked modified potato starch into a carboxymethyl cellulose solution, stirring at 400rpm for 30min to uniformly mix, adjusting the pH of the solution to 6 by using 1mol/L HCl after uniform mixing, and standing for more than 12h to remove bubbles in the solution;
4) Pouring the mixed solution into a precooling mold, standing for 30min, covering a mold cover, placing the mold cover in a freezing refrigerator at the temperature of minus 40 ℃ for prefreezing for 4h, removing the mold cover after prefreezing is finished, and placing the mold carrying the sample in a freezing drying box for freezing and drying for 72h at the temperature of minus 60 ℃ and minus 0.1MPa to obtain the degradable starch hemostatic sponge.
Experimental example 1:
the hemostatic sponges obtained in the examples and the hemostatic sponges obtained in the comparative examples were placed in water, and the dissolution was observed:
whether the hemostatic sponge can be completely dissolved in water of 36.2 ℃ within 6 hours or not by 1 g | |
Example 1 | Is that |
Example 2 | Is that |
Example 3 | Is that |
Comparative example | Whether or not |
As can be seen from the above table, the hemostatic sponge of the pad core of the hemostatic sponge obtained in the example can be completely dissolved in water at 36.2 ℃ for 6 hours in 1 g of the hemostatic sponge of the pad core of the hemostatic sponge, while the hemostatic sponge of the comparative example cannot be completely dissolved in 6 hours.
Experimental example 2:
based on example 1, the effect of different amounts of 0.25% (v/v) glutaraldehyde solution added on the dissolution of the hemostatic sponge in water of the resulting hemostatic sponge pad core was investigated:
from the above table, the adding amount of 0.25% (v/v) glutaraldehyde solution affects the dissolution of the hemostatic sponge of the obtained hemostatic sponge pad core in water, the adding amount of 0.25% (v/v) glutaraldehyde solution is in the range of (2.8-3.2) mL, 1 gram of hemostatic sponge of the obtained hemostatic sponge pad core can be completely dissolved within 6 hours in water at 36.2 ℃, and the other added amounts of hemostatic sponge of the obtained hemostatic sponge pad core cannot be completely dissolved, and the analysis reason is that too much 0.25% (v/v) glutaraldehyde solution is added, which causes too tight connection of different tissue components in the hemostatic sponge of the hemostatic sponge pad core, thereby affecting the solubility of the hemostatic sponge pad core in water; too little addition of 0.25% (v/v) glutaraldehyde solution results in loose connection of different tissue components in the hemostatic sponge of the hemostatic sponge pad core, which affects the hemostatic effect of the hemostatic sponge pad core, so that the addition of 0.25% (v/v) glutaraldehyde solution is suitable in the range of (2.8-3.2) mL.
The above description is intended to describe in detail the preferred embodiments of the present invention, but the embodiments are not intended to limit the scope of the claims of the present invention, and all equivalent changes and modifications made within the technical spirit of the present invention should fall within the scope of the claims of the present invention.
Claims (2)
1. Hemostatic sponge pad core, its characterized in that: the preparation method comprises the following steps:
1) Preparing raw materials according to the proportion: gelatin (9.5-10.5) g, distilled water (88-92) mL, 0.25% v/v glutaraldehyde solution (2.8-3.2) mL, 0.5% v/v formaldehyde (2.4-2.6) mL;
2) Pouring gelatin into distilled water, soaking for 10 min, heating in water bath at 60-70 deg.C, stirring for dissolving, adding 0.5% v/v formaldehyde, stirring at high speed, and stirring at 200-400rpm for 20-30min;
3) Injecting the mixed solution obtained in the previous step into moulds with different specifications, paving water-absorbing pad cores at the bottom of the moulds, pre-freezing at-40 to-80 ℃, and then performing freeze drying to obtain the water-absorbing pad cores with sponges;
4) And (2) crosslinking the water-absorbing pad core with the sponge obtained in the previous step by adopting 0.25% v/v glutaraldehyde solution, washing the water-absorbing pad core with distilled water for 2-4 times after crosslinking, then carrying out freeze drying and forming again, pasting an adhesive tape on the bottom of the hemostatic sponge pad core, sealing, and then carrying out cobalt-60 sterilization to obtain the hemostatic sponge pad core, wherein in water at 36.2 ℃,1 g of hemostatic sponge of the hemostatic sponge pad core is completely dissolved within 6 hours.
2. The hemostatic sponge cushion core according to claim 1, wherein: the raw materials prepared according to the proportion in step 1) are gelatin 10g, distilled water 90g, 0.25% v/v glutaraldehyde solution 3ml, 0.5% formaldehyde 2.5 ml.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111144981.3A CN113663120B (en) | 2021-09-28 | 2021-09-28 | Hemostatic sponge cushion core and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111144981.3A CN113663120B (en) | 2021-09-28 | 2021-09-28 | Hemostatic sponge cushion core and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113663120A CN113663120A (en) | 2021-11-19 |
CN113663120B true CN113663120B (en) | 2022-10-28 |
Family
ID=78550477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111144981.3A Active CN113663120B (en) | 2021-09-28 | 2021-09-28 | Hemostatic sponge cushion core and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113663120B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114177337B (en) * | 2021-12-07 | 2022-10-28 | 桂林福康森医疗器械有限公司 | Special hemostatic dressing for dialysis and preparation method thereof |
CN114272432B (en) * | 2021-12-22 | 2023-03-17 | 山东百多安医疗器械股份有限公司 | Preparation method of novel hemostatic sponge composite material for cerebral surgery |
WO2025051139A1 (en) * | 2023-09-08 | 2025-03-13 | Anti-Microbial Savior Bioteq Co., Ltd. | Artificial dressing, use of artificial dressing for promoting wound healing and method of manufacturing artificial dressing |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108478849A (en) * | 2018-02-07 | 2018-09-04 | 广州迈普再生医学科技股份有限公司 | One kind is absorbable can to stick styptic sponge and preparation method thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100376293C (en) * | 2006-03-13 | 2008-03-26 | 西北大学 | A method for preparing biodegradable scaffold material for tissue engineering |
CN201346260Y (en) * | 2009-01-06 | 2009-11-18 | 王纯斌 | Wound protection plaster for hemostatic sponge |
CN101695581A (en) * | 2009-10-26 | 2010-04-21 | 西北大学 | Method for preparing human-like collagen haemostatic sponge in scale |
CN103756005B (en) * | 2014-01-09 | 2016-03-23 | 山东省淡水渔业研究院 | A kind of Composite collagen sponge and preparation method thereof |
TW201932124A (en) * | 2018-01-18 | 2019-08-16 | 近鎰生技股份有限公司 | Hemostatic material, preparation method thereof and pharmaceutical composition containing the same |
-
2021
- 2021-09-28 CN CN202111144981.3A patent/CN113663120B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108478849A (en) * | 2018-02-07 | 2018-09-04 | 广州迈普再生医学科技股份有限公司 | One kind is absorbable can to stick styptic sponge and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
Cytotoxicity evaluation of gelatin sponges prepared with different cross-linking agents;KEZBAN ULUBAYRAM, et al;《J. Biomater. Sci. Polymer Edn》;20120402;第13卷(第11期);1203-1219 * |
Also Published As
Publication number | Publication date |
---|---|
CN113663120A (en) | 2021-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113663120B (en) | Hemostatic sponge cushion core and preparation method thereof | |
CN111991608B (en) | Wound surface covering and preparation method thereof | |
EP0095892A1 (en) | Wound-covering materials | |
CN107596438B (en) | A kind of natural polysaccharide self-healing hydrogel of injectable and the preparation method and application thereof | |
CN113769156A (en) | Hybrid fiber sponge with functions of hemostasis and wound repair and preparation method thereof | |
Zhang et al. | Water-retaining and separable adhesive hydrogel dressing for wound healing without secondary damage | |
JP2017522162A (en) | Polymer foam composition, method for producing polymer foam using the same, and polymer foam for packing | |
CN114146215A (en) | Injectable hydrogel with antibacterial, antioxidant and hemostatic effects and preparation method and application thereof | |
CN107551312B (en) | Flocculent collagen hemostatic fiber and preparation method thereof | |
CN103159967B (en) | Preparation method of collagen-based sponge wound dressing with self-anti-inflammatory function | |
KR20020000580A (en) | Wound dressing containing a chitosan/PVA (polyvinylalcohol) hydrogel and process for preparing thereof | |
JP2021518803A (en) | Chitosan fibrous sponge structure medical dressing and its manufacturing method | |
KR100748348B1 (en) | Method of manufacturing hydrogel for wound treatment using irradiation technology | |
CN111467560B (en) | Medical hemostatic dressing, preparation method and application thereof | |
CN106975098B (en) | Composite polysaccharide hemostatic composition and preparation method and application thereof | |
CN113750287B (en) | Water-soluble hemostatic sponge and preparation method thereof | |
CN109111591A (en) | It is a kind of carry medicine styptic sponge preparation method and its preparation load medicine styptic sponge | |
CN111228562B (en) | Starch hemostatic sponge and preparation method and application thereof | |
CN112007201B (en) | Adhesive antibacterial hemostatic sponge and preparation method thereof | |
CN113144280A (en) | Intelligent antibacterial hydrogel and application thereof | |
CN112870451A (en) | Nerve sheath tube and preparation method and application thereof | |
CN108815560B (en) | Porous tissue plugging material, preparation method thereof and plugging product | |
CN1775302A (en) | Preparation method of chitosan-gelatin sponge wound dressing | |
CN116983462A (en) | Multifunctional hemostatic composite sponge, preparation method and application | |
CN110538344B (en) | Medical degradable hemostatic material and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |